DaVita Clinical Research Campaign Shares Stories from Participants and Researchers
DaVita Clinical Research launched its "Inspired to Give" campaign
DaVita Clinical Research® launched its “Inspired to Give” campaign, which started November 12 and runs through February 2014, features both clinical trial participants and researchers sharing their personal experiences with clinical research. The series utilizes video, Instagram and Twitter to spread the word. The campaign asks individuals to share what inspires them to give to the medical community and humankind through participation in clinical trials.
“We find that the driving force for most who participate in clinical trials is that they have someone close to them who has a disease or illness and they want to help that person,” said DCR Chief Scientific Officer Dr. Harry Alcorn. “And in additional to being altruistic, trial participants ultimately play a key role in the future of health care by helping to develop medicine for others.”
You can read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
